HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]

Abstract

Bretoni A, Ferrario L, Foglia E. Clinicoecon Outcomes Res. 2019;11:283–300.The authors of this paper have advised us that there is a typographical error in one of the headings in Table 4. Table 4 occupies two pages and while being continued from page 292 onto page 293, a wrong table header was recorded. The table heading “Effectiveness profile” should instead be replaced by “Equity aspects” on page 293.Read the original article